Obesity Rates Are Still Rising Despite Ozempic — Why GLP-1s Alone Can't Fix the Epidemic

The GLP-1 revolution is real. Millions of Americans have lost meaningful weight on semaglutide and tirzepatide. Doctors are calling these the most effective obesity medications ever developed. The FDA has approved oral versions, Medicare is expanding coverage, and prices are falling faster than anyone predicted two years ago.

And yet: obesity rates in America are still rising.

A new analysis from University of Virginia obesity medicine researcher Dr. Cate Varney lays out the paradox clearly. The drugs work — powerfully, at the individual level. But between access gaps, affordability barriers, discontinuation rates, and the sheer scale of the epidemic, GLP-1 medications have not yet made a dent in the national numbers.

Understanding why requires separating two very different questions: Do GLP-1 drugs work? (Yes, emphatically.) And: Will they solve the obesity epidemic? (Not automatically, and not at current access rates.)

The 2030 Projection That Should Alarm Everyone

Back in 2019, researchers published a projection in the New England Journal of Medicine that has loomed over public health ever since: by 2030, nearly half of all American adults will have obesity — defined as a body mass index of 30 or higher. More striking still: in every single state, at least 35% of adults are projected to meet that threshold. No state will be spared.

That projection was made before semaglutide became a household name. Before Wegovy. Before Zepbound. Before the oral GLP-1 pill. The question now is whether the GLP-1 era has changed the math — and the honest answer is: not enough, yet.

"The CDC has been tracking obesity rates since the 1980s, and they've steadily trended higher," said Dr. Varney, director of obesity medicine at UVA Health and faculty at the University of Virginia School of Medicine. The trajectory hasn't reversed. It has, at most, begun to slow.

A Flicker of Hope in the Gallup Data

There was one genuinely encouraging signal. The 2024 Gallup National Health and Well-Being Index — one of the broadest population-level health surveys in the United States — showed, for the first time, a decline in reported obesity rates.

"Everybody kind of scratched their head a bit, and we realized it correlated to when we started using GLP-1 medications," said Dr. Varney.

The timing is not coincidental. 2022-2024 was the period of explosive GLP-1 prescribing growth — a 442% increase in fills between 2021 and 2023 for semaglutide alone. If those prescriptions translated into meaningful, sustained weight loss for even a fraction of users, you'd expect to see exactly this kind of early signal in population-level data.

But one year of declining Gallup data, in a trend that has been rising for four decades, is not a reversal. It's a flicker. Whether it becomes a sustained trend depends entirely on what happens next with access, affordability, and adherence.

The Access Gap: Why 95%+ of Eligible Patients Aren't on GLP-1s

Here's the core problem: GLP-1 medications are extraordinarily effective for the people who take them. But the people who actually take them represent a tiny fraction of those who could benefit.

Estimates suggest that somewhere between 70-100 million Americans have obesity or overweight with weight-related comorbidities — the population that would qualify for GLP-1 therapy under current FDA labeling. As of early 2026, active GLP-1 prescriptions for weight management number in the low millions — roughly 3-5% of the eligible population.

The access gap has multiple drivers:

• Cost: Until recently, brand-name GLP-1 medications cost $1,000 or more per month without insurance. Even with the rapid pricing changes of early 2026 — TrumpRx at ~$350/month, GoodRx oral semaglutide at $149/month, Medicare's $50/month Zepbound deal — a significant portion of the eligible population still faces unaffordable out-of-pocket costs.
• Insurance barriers: Prior authorization requirements, BMI cutoffs, and outright coverage denials continue to block many patients who have both medical need and some insurance coverage from accessing these medications.
• Provider access: Primary care physicians — who see the vast majority of patients with obesity — are often undertrained in obesity medicine and underconfident in prescribing GLP-1 medications. Many patients are never offered the conversation.
• Stigma: Despite growing cultural acceptance, obesity is still widely perceived as a lifestyle failure rather than a chronic disease. Many patients don't seek treatment; many providers don't initiate it.

The Discontinuation Problem

Even among the 3-5% who do start GLP-1 therapy, a significant proportion stop — and when they do, the weight comes back.

A landmark BMJ meta-analysis published in January 2026, reviewing 9,341 patients across 37 studies, found that patients regained nearly all their lost weight within 1.5-1.7 years of stopping GLP-1 medications. The regain rate was approximately 1.8 lbs per month for semaglutide and tirzepatide users — faster than the general drug average, though partially offset by the larger initial weight loss.

Discontinuation happens for many reasons: side effects, cost, the erroneous belief that a finite course is sufficient, and insurance coverage lapses. Every discontinuation effectively resets the patient's weight trajectory — meaning the population-level benefit of GLP-1 prescribing is significantly smaller than the number of prescriptions written might suggest.

For GLP-1 medications to genuinely bend the obesity curve, patients need to stay on them long-term. That requires affordable, sustained access — which the U.S. healthcare system has not yet delivered at scale.

What Would Actually Move the Needle

Dr. Varney and other obesity medicine specialists describe a clearer picture of what population-level impact would actually require:

Dramatically broader insurance coverage. If GLP-1 medications were covered similarly to statins or blood pressure medications — with minimal copays and no prior authorization barriers — uptake would increase by an estimated 10-20x. The Medicare Zepbound deal ($50/month) is a model, but it covers one drug, for one payer, for one population segment. It needs to scale.

Primary care integration. Obesity medicine needs to become a routine part of primary care, not a specialty referral. The 2026 FDA expansion of who qualifies for TRT — and analogous discussions about broadening GLP-1 eligibility — signal that prescribing criteria are moving in the right direction. But provider education needs to keep pace.

Sustained treatment, not episodic courses. The emerging scientific consensus — reinforced by the Oxford/BMJ regain study and the WHO's new guidelines — is that obesity is a chronic disease requiring long-term management. Healthcare systems, insurers, and patients all need to internalize this model. A 3-month prescription isn't treatment; it's a trial.

Addressing the 2030 window. The NEJM's 50%-by-2030 projection is now only four years away. Even with accelerating GLP-1 uptake, reaching enough of the eligible population in that timeframe to avoid that projection would require something close to a public health mobilization — a scale of access expansion that makes even the recent pricing breakthroughs look modest.

The Individual vs. the Epidemic

None of this diminishes what GLP-1 medications have achieved at the individual level. For patients who access them, stick with them, and receive appropriate monitoring, these drugs are genuinely life-changing. The cardiovascular, metabolic, and quality-of-life benefits are well-documented and growing with each new trial.

The paradox is that a therapy so effective at the individual level is not automatically effective at the population level — not because the science is wrong, but because healthcare systems, economics, and social structures determine who actually gets access to transformative treatments.

"GLP-1 medications have changed how people eat, shop, and even relate to one another," noted the UVA analysis. They're reshaping food consumption, restaurant habits, and cultural norms around weight. That's real. But reshaping a four-decade obesity trend requires more than a drug — it requires the infrastructure to get that drug to the people who need it, at a price they can sustain, for as long as it takes.

We're closer than we've ever been. Whether we close the gap before 2030 is a policy question as much as a medical one.

If GLP-1s work, why are obesity rates still going up?

Because only a small fraction of eligible patients are actually on GLP-1 therapy — estimated at 3-5% of those who medically qualify. The drugs work powerfully for individuals who take them, but access, cost, and insurance barriers keep the vast majority of eligible patients untreated. Population trends move slowly even when individual treatments work well.

Will obesity rates start declining as GLP-1s become more affordable?

Potentially, yes — the 2024 Gallup data showed the first-ever population-level decline in obesity rates, correlated with GLP-1 uptake. As prices fall (oral semaglutide at $149/month, Medicare Zepbound at $50/month), more patients can access treatment and maintain it long-term. Sustained broader access could begin moving national numbers meaningfully within the next 3-5 years.

Are we still on track for 50% adult obesity by 2030?

Possibly, though the GLP-1 era may soften the trajectory. The NEJM 2030 projection was made before widespread GLP-1 prescribing. Whether actual 2030 rates come in below that threshold depends heavily on how rapidly access expands over the next four years.